Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both
- PMID: 11742048
- DOI: 10.1056/NEJMoa011503
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both
Abstract
Background: Patent foramen ovale and atrial septal aneurysm have been identified as potential risk factors for stroke, but information about their effect on the risk of recurrent stroke is limited. We studied the risks of recurrent cerebrovascular events associated with these cardiac abnormalities.
Methods: A total of 581 patients (age, 18 to 55 years) who had had an ischemic stroke of unknown origin within the preceding three months were consecutively enrolled at 30 neurology departments. All patients received aspirin (300 mg per day) for secondary prevention.
Results: After four years, the risk of recurrent stroke was 2.3 percent (95 percent confidence interval, 0.3 to 4.3 percent) among the patients with patent foramen ovale alone, 15.2 percent (95 percent confidence interval, 1.8 to 28.6 percent) among the patients with both patent foramen ovale and atrial septal aneurysm, and 4.2 percent (95 percent confidence interval, 1.8 to 6.6 percent) among the patients with neither of these cardiac abnormalities. There were no recurrences among the patients with an atrial septal aneurysm alone. The presence of both cardiac abnormalities was a significant predictor of an increased risk of recurrent stroke (hazard ratio for the comparison with the absence of these abnormalities, 4.17; 95 percent confidence interval, 1.47 to 11.84), whereas isolated patent foramen ovale, whether small or large, was not.
Conclusions: Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered.
Similar articles
-
Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm.Am Heart J. 1995 Nov;130(5):1083-8. doi: 10.1016/0002-8703(95)90212-0. Am Heart J. 1995. PMID: 7484740
-
Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale.Int J Cardiol. 2005 May 11;101(1):77-82. doi: 10.1016/j.ijcard.2004.03.005. Int J Cardiol. 2005. PMID: 15860387
-
Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention.Stroke. 1994 Apr;25(4):782-6. doi: 10.1161/01.str.25.4.782. Stroke. 1994. PMID: 8160221
-
[Cryptogenic stroke and patent foramen ovale].Ther Umsch. 2003 Sep;60(9):553-61. doi: 10.1024/0040-5930.60.9.553. Ther Umsch. 2003. PMID: 14579624 Review. German.
-
Patent foramen ovale and atrial septal aneurysm in cryptogenic stroke.Postgrad Med J. 2007 Mar;83(977):173-7. doi: 10.1136/pgmj.2006.051094. Postgrad Med J. 2007. PMID: 17344571 Free PMC article. Review.
Cited by
-
Patent Foramen Ovale and Other Cardiopathies as Causes of Embolic Stroke With Unknown Source.J Stroke. 2024 Sep;26(3):349-359. doi: 10.5853/jos.2024.02670. Epub 2024 Sep 30. J Stroke. 2024. PMID: 39396831 Free PMC article. Review.
-
Updates on Patent Foramen Ovale (PFO) Closure.Curr Cardiol Rep. 2024 Jul;26(7):735-746. doi: 10.1007/s11886-024-02073-y. Epub 2024 Jun 24. Curr Cardiol Rep. 2024. PMID: 38913234 Review.
-
Prevalence and characteristics of patent foramen ovale in a sample of Egyptian population: a computed tomography study.Egypt Heart J. 2024 Jun 10;76(1):73. doi: 10.1186/s43044-024-00504-3. Egypt Heart J. 2024. PMID: 38856789 Free PMC article.
-
European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke.Eur Stroke J. 2024 Dec;9(4):800-834. doi: 10.1177/23969873241247978. Epub 2024 May 16. Eur Stroke J. 2024. PMID: 38752755 Free PMC article.
-
Atrial Septal Abnormalities and Cryptogenic Stroke: A Cross-Sectional Study.Cardiovasc Hematol Disord Drug Targets. 2024;24(1):40-46. doi: 10.2174/011871529X294809240415070950. Cardiovasc Hematol Disord Drug Targets. 2024. PMID: 38685781
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical